Bromocriptine for Inappropriate Thyrotropin Secretion
- JOHN M.C. CONNELL, M.B.;
- DOUGLAS C. MCCRUDEN, B.SC.;
- D.L. DAVIES, M.D.; and
- W. DONALD ALEXANDER, M.D.
- Gardiner Institute, Western Infirmary, Glasgow G11 6NT, Scotland Royal Infirmary; Glasgow G4, Scotland
Excerpt
To the editor: In the concluding paragraphs of the National Institutes of Health conference on inappropriate thyroid stimulating hormone (TSH) secretion, somatostatin or dopamine analogues were suggested as possible appropriate therapies in this condition (1). We write to report preliminary results of use of the dopamine agonist bromocriptine (Parlodel, Sandoz, Ltd, London, United Kingdom) in this condition.
A 56-year-old white man presented with thyrotoxicosis in 1978, with an elevated serum free thyroxine (T4) of 164 nmol/L (normal range, 55 to 144 nmol/L); free triiodothyroxine (T3), 3 nmol/L (normal range, 0.9 to 2.8 nmol/L); and early (20 minutes) iodine uptake, 25%
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
